Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Cancer

Disease Area

More than METs the Eye

| Jonathan James |

The role of different types of MET mutation in lung cancer could demand a rethink of treatments.

Tools & Techniques

Right for Patients?

| Ellen Sigal |

“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.

Tools & Techniques

Express Insight into Bladder Cancer

| Michael Schubert |

Looking at miRNA expression levels may improve our ability to subtype bladder cancers and provide the most appropriate and effective treatment

Disease Area

Real-Time Tumor Analysis

| William Aryitey |

MALDI and a SpiderMass device could save valuable surgery time

Disease Area

Markers for Prognostic Progress

| Ana Robles |

Better lung cancer treatment through biomarkers

Outside the Lab

Lessons Learned, with Pier Paolo Pandolfi

| Pier Paolo Pandolfi |

A giant of leukemia research and treatment discusses his career

Tools & Techniques

Screen Test for Spec

| Joanna Cummings |

How ATR-FTIR spectroscopy could lead to less invasive cancer prescreening

Research Field

Staying On Target

| Roisin McGuigan |

What characteristics make a cancer therapy more likely to effectively treat disease?

Disease Area

Cost-effective Cancer Checks

| William Aryitey |

Testing the whole population of women for breast/ovarian cancers mat be more cost-effective than current methods

Disease Area

Variant Database Collaborations – for Cancer and Beyond

| Obi Griffith and Heidi Rehm |

It's important to research relevant academic papers, but it's equally important to make sure it's still relevant


Sister Publications

You might be interested in our Sister Publications:

Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register